Home » Newsletters » BioWorld Science

BioWorld Science

April 29, 1997

View Archived Issues

Angiotensin II antagonist effective for progression of diabetic nephropathy

FDA approves new labeling for Bristol-Myers Squibb's Pravachol

Agents for hyperandrogenic disorders from Merck & Co.

Delta-opioid agonists/antagonists described by SmithKline Beecham

Sanofi describes selective NK3 receptor antagonists

SKB reports neuronal calcium channel antagonists

NOS inhibitors disclosed by Searle

Novel immunosuppressants from Takeda

Radiosensitizing taxanes prepared by Florida State University

Compounds combining PAF antagonist and 5-ASA claimed by Uriach for IBD

Pharmacia & Upjohn discloses new antimicrobial agents

Pharmacokinetic data for pentafuside in rodents, monkeys and man

Pharmacia & Upjohn prepares potent and selective dopamine D4 antagonist

PD-170262: potent and selective PDGF TK inhibitor from Parke-Davis

DuPont Merck describes potent, orally bioavailable cyclic urea HIV protease inhibitor

Potent and selective iNOS inhibitor disclosed by Merck & Co.

SKB describes potent, selective IL-8beta receptor antagonists

Potent antitumor farnesyltransferase inhibitors discovered by Parke-Davis

MDL-101731 shows potent antiviral activity in vitro

Target of action of AR-177 elucidated

ESI Lederle launches generic acyclovir

Joint venture created to develop calanolide A as anti-HIV treatment

Neuraminidase inhibitors highlighted at antiviral conference

TheraTech reacquires marketing rights to testosterone patch product

Neurex's blood pressure treatment up for FDA advisory panel review in June

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...